Last September, a 51-year-old marketing director named Greg in Austin told his prescriber something that captures the tesamorelin experience better than most clinical summaries. "I lost two inches off my waist in four months and gained a pound on the scale," he said. "My wife thought the tape measure was broken." His DEXA scan told a cleaner story: visceral fat down 16 percent, lean mass up slightly. That pattern, body composition shifting while total weight barely moves, is the signature tesamorelin result. And it's exactly what the published Phase III data predicts.
The Falutz NEJM trials (2007 and 2008) remain the backbone of everything we know about tesamorelin. Approximately 15 to 18 percent reduction in visceral fat over 26 weeks of daily 2 mg dosing in HIV-associated lipodystrophy patients. Secondary benefits: IGF-1 normalization, lean mass preservation, lipid profile improvements, modest cardiovascular risk marker changes. Tesamorelin is a stabilized GHRH analog. The branded version (Egrifta) is FDA-approved for HIV-associated lipodystrophy. Compounded tesamorelin is prescribed off-label by licensed pharmacies.
Here's what the research actually shows, where the evidence is strong, where it gets thinner, and what it means for off-label compounded use.
Visceral Fat: The Core Finding
The visceral fat reduction is the whole ballgame for tesamorelin's clinical identity. It's what got Egrifta approved, and it's the most reproducible finding across trials.
From the Falutz pivotal data:
- 15 to 18 percent reduction in visceral fat measured by CT imaging over 26 weeks
- Effect sustained with continued therapy
- Effect reversed when therapy was discontinued
- Subcutaneous fat was largely preserved
- Lean body mass preserved or modestly increased
That last point matters more than most people realize. A lot of interventions that reduce visceral fat also chew into subcutaneous stores and lean tissue. Tesamorelin's selectivity for visceral adipose tissue is unusual and clinically relevant.
Why does visceral fat get its own category of concern? Because it behaves differently than the fat you can pinch. Visceral adipose tissue (the fat packed around abdominal organs) produces more inflammatory cytokines, contributes more to insulin resistance, and has stronger associations with cardiovascular risk than subcutaneous fat. Reducing it preferentially, rather than just dropping total body weight, has theoretical and observational support for cardiometabolic benefit that outpaces what the scale alone would suggest.
Think of it like this: two people can weigh the same, wear the same pants size, and have wildly different metabolic risk profiles based on where their fat lives. Tesamorelin targets the more dangerous compartment.
IGF-1 Response and What "Normal" Looks Like
Tesamorelin reliably elevates IGF-1 from baseline. In most patients, it brings levels into the upper half of the age-adjusted normal range within 8 to 12 weeks.
The IGF-1 bump is more pronounced with tesamorelin than with sermorelin at typical doses. This makes sense pharmacologically: tesamorelin's longer half-life and more sustained GHRH receptor activity per injection cycle means more total GH secretion per day.
The clinical target is the upper half of the age-adjusted normal range, not above it. When IGF-1 creeps above the reference ceiling on quarterly labs, dose gets reduced. This is one reason monitoring matters and why prescribers who skip follow-up bloodwork are doing their patients a disservice.
Body Composition: Where the Scale Lies to You
The body composition picture from the trials looks like this:
Get provider-reviewed GLP-1 therapy
Side effects are manageable with the right support. A licensed provider can adjust your dose when you need it.
Start Free Assessment →- Visceral fat down
- Lean mass preserved or slightly up
- Subcutaneous fat largely preserved
- Total weight relatively unchanged
This is exactly the scenario that frustrates people who only use a bathroom scale. If you lose two pounds of visceral fat and gain one and a half pounds of lean tissue, the scale says you've lost half a pound. Meanwhile your waist circumference is down, your pants fit differently, and your metabolic labs look better.
DEXA scans and CT/MRI body composition assessments catch these changes. The scale, mostly, does not.
Lipid Improvements (Real but Modest)
The pivotal trials documented lipid changes in the right direction:
- Reduction in triglycerides
- Improvement in total cholesterol to HDL ratio
- Reduction in non-HDL cholesterol
- HDL changes were variable
The boring truth: these improvements are smaller than what a statin produces. They're directional, consistent with reduced visceral adiposity and improved hepatic lipid handling, and clinically encouraging. They are not a replacement for lipid-lowering medication in someone who needs one.
Cardiovascular and Inflammatory Markers
Beyond lipids, the trials looked at broader cardiovascular markers:
- Modest reduction in C-reactive protein
- Improvement in adiponectin levels
- Variable effects on blood pressure
- No significant change in cardiovascular event rates over trial duration
Here's the thing: these are surrogate markers, not hard endpoints. CRP going down and adiponectin going up are good signs. Whether those changes, at the magnitudes observed over 26-week trials, translate into fewer heart attacks over a decade is something nobody can tell you yet. The data doesn't exist.
Some emerging research also suggests tesamorelin may reduce hepatic fat content (liver steatosis), likely secondary to the visceral fat mechanism. Studies have looked at this in both HIV-lipodystrophy populations and non-alcoholic fatty liver disease. The effect appears real, but the clinical significance in non-HIV populations is still being characterized.
How Tesamorelin Compares to Sermorelin
This is the question that comes up constantly, so let's be direct about it.
Tesamorelin is a stabilized GHRH analog with a longer half-life. Stronger GH and IGF-1 response per dose. Solid visceral fat reduction documented in Phase III trials. Standard 2 mg daily dose. More expensive per month. More pronounced side effect profile.
Sermorelin is a native GHRH fragment with a shorter half-life. Milder GH and IGF-1 response. Best evidence is for sleep architecture improvement. Variable dose range. Lower cost per month. Gentler side effect profile.
My honest take: if visceral fat reduction is your primary goal and you can afford it, tesamorelin is the better-supported choice. Full stop. If you're looking for gentle GH-axis support with sleep benefits and your visceral fat situation isn't urgent, sermorelin is often a better fit and easier on the wallet.
Comparing them head-to-head is a bit like comparing a targeted antibiotic to a broad-spectrum one. They work on the same axis but with different intensities and trade-offs.
What Tesamorelin Will Not Do
This is where I'd rather be honest up front than deal with disappointed patients later.
Tesamorelin will not produce rapid, significant weight loss. It will not approach what GLP-1 medications do to total body weight. It will not bypass the need for training and nutrition. It will not produce dramatic body transformations in weeks. It will not work meaningfully if taken inconsistently. And it will not extend lifespan (no peptide trial has demonstrated that).
The benefits are real. They're well-documented. They're meaningful within their scope. But the scope has boundaries.
Staying on It: Cumulative Effects and Discontinuation
The Egrifta trials ran 26 weeks. Compounded practice often extends use beyond that. What the longer clinical picture shows:
- Visceral fat reduction tends to maintain with continued therapy
- IGF-1 effects remain stable with continued dosing
- Lipid changes maintain with continued therapy
- Body composition shifts continue developing slowly past 26 weeks
- Discontinuation produces regression of effects over months
That last point is important and undersold. Tesamorelin isn't a one-course fix. Stop it, and the visceral fat comes back over time. Patients who cycle on and off should understand this going in.
Patients in clinical trials also reported subjective improvements in energy levels, recovery from physical activity, sleep quality, body image, and general well-being. These are quality-of-life endpoints rather than disease outcomes, but they're clinically meaningful (and often the reason patients stay compliant).
The Off-Label Question
Compounded tesamorelin is used off-label for general visceral fat reduction in non-HIV patients, body composition optimization, GH-axis support in age-related decline, and in combination with other compounded peptides.
The off-label rationale extends the documented mechanism (visceral fat reduction, IGF-1 elevation, body composition effects) to populations beyond the HIV-lipodystrophy trials. Whether the magnitude of effect seen in that specific population translates identically to a 48-year-old non-HIV adult is not directly proven by Phase III data. Smaller studies and accumulated clinical experience suggest similar directional effects, but the evidence base is thinner.
That's an honest framing, not a reason to avoid it. Plenty of well-established compounded medications are used off-label based on mechanism-of-action reasoning. It just means the confidence interval is wider than what you'd get from a drug with an indication in your exact population.
FAQ
What is the strongest evidence for tesamorelin? Visceral fat reduction, established in the Falutz NEJM Phase III trials for HIV-associated lipodystrophy. This is the finding that secured FDA approval for the branded version (Egrifta).
How much visceral fat can I expect to lose? Trial data showed roughly 15 to 18 percent reduction in visceral fat over 26 weeks at 2 mg daily. Individual results vary based on baseline visceral fat levels, adherence, and lifestyle factors.
Is tesamorelin a weight loss drug? Not in the conventional sense. Scale weight often barely changes because visceral fat reduction is accompanied by lean mass preservation. The changes show up on body composition testing, waist measurements, and metabolic labs, not necessarily on the scale.
Will my IGF-1 go too high? Tesamorelin reliably elevates IGF-1. The clinical target is the upper half of the age-adjusted normal range. Quarterly monitoring catches patients whose IGF-1 climbs above normal so the dose can be adjusted.
How long does it take to see results? IGF-1 changes are detectable within weeks. Visceral fat changes typically become measurable around 12 to 26 weeks of consistent daily therapy.
Does the effect last if I stop? No. The trials showed that visceral fat reduction reversed after discontinuation. Continued therapy is needed to maintain the effect.
---
Compounded tesamorelin is prescribed off-label for adults; the FDA-approved indication for the branded version (Egrifta) is HIV-associated lipodystrophy. Compounded tesamorelin is prepared by licensed pharmacies for individual patients based on a prescriber's clinical judgment. This article is educational only and does not constitute medical advice. Talk to a qualified clinician before starting any peptide therapy.
Related reading: Tesamorelin Visceral Fat Protocol | Tesamorelin Dosage Protocols | Tesamorelin Side Effects Explained | Tesamorelin for HIV Lipodystrophy | Order Compounded Tesamorelin
---
Not FDA-approved. Compounded peptides are prepared by licensed 503A pharmacies for individual patients based on a prescriber's clinical judgment. FormBlends is not a medical practice. Individual results vary. Consult a licensed clinician before starting any peptide therapy.